Conclusions from MonumenTAL-1 Study in Multiple Myeloma
Following a review of MonumenTAL-1, experts on multiple myeloma discuss the conclusions from the clinical trial and provide their impressions of the findings.
EP: 1.How Are Patients with Multiple Myeloma (MM) Diagnosed and Staged?
EP: 2.Overview of Relapsed/Refractory Multiple Myeloma
EP: 3.MonumenTAL-1: Talquetamab in Relapsed/Refractory MM
EP: 4.Talquetamab Safety Profile in Relapsed/Refractory MM
EP: 5.Clinical Strategies for Adverse Event Management in Patients With Multiple Myeloma Receiving Talquetamab
EP: 6.GPRC5D-Related Oral Adverse Events in Multiple Myeloma
EP: 7.MonumenTAL-1: Proactive Management of Oral Toxicities
EP: 8.Multiple Myeloma: Educating Patients on Oral Toxicity Management
EP: 9.Approaches for Managing Dermatologic Adverse Events from Talquetamab in Multiple Myeloma
EP: 10.Conclusions from MonumenTAL-1 Study in Multiple Myeloma
This is a video synopsis/summary of a Between The Lines series featuring Donna Catamero, ANP-BC, OCN, CCRC; Cesar Rodriguez, MD; and Saad Usmani, MD, MBA, FACP.
In conclusion, talquetamab induces deep, durable responses in heavily pretreated myeloma but has unique, mostly manageable toxicities requiring mitigation to sustain therapy. Up-front patient education on expected adverse effects and self-care, close monitoring and early intervention, and prompt dose modifications when needed facilitate tolerance. Skin changes typically resolve with symptomatic relief from barrier creams. Future studies should examine talquetamab in earlier lines to widen accessibility. As experience accrues, best practices for balancing efficacy and quality of life will evolve through ongoing clinician collaboration.
Video synopsis is AI generated and reviewed by Cancer Network® editorial staff.
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
